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Analysis of circulating tumor DNA from the cell-free fraction
of blood can detect tumor recurrence and progression in
liver cancer, especially extrahepatic metastasis within 2
years.
BACKGROUND & AIMS: Circulating tumor DNA (ctDNA) car-
rying tumor-speciﬁc sequence alterations has been found in the
cell-free fraction of blood. Liver cancer tumor specimens are
difﬁcult to obtain, and noninvasive methods are required to
assess cancer progression and characterize underlying genomic
features.
METHODS: We analyzed 46 patients with hepatocellular
carcinoma who underwent hepatectomy or liver trans-
plantation and for whom whole-genome sequencing data was
available. We designed personalized assays targeting somatic
rearrangements of each tumor to quantify serum ctDNA.
Exome sequencing was performed using cell-free DNA paired
primary tumor tissue DNA from a patient with recurrent liver
cancer after transcatheter arterial chemoembolization
(TACE).
RESULTS: We successfully detected ctDNA from 100 mL of
serum samples in 7 of the 46 patients before surgery,
increasing with disease progression. The cumulative incidence
of recurrence and extrahepatic metastasis in the ctDNA-positive
group were statistically signiﬁcantly worse than in the ctDNA-
negative group (P ¼ .0102 and .0386, respectively). Multivar-
iate analysis identiﬁed ctDNA (OR 6.10; 95% CI, 1.11–33.33,
P ¼ .038) as an independent predictor of microscopic vascular
invasion of the portal vein (VP). We identiﬁed 45 non-
synonymous somatic mutations in cell-free DNA after TACE and
71 nonsynonymous somatic mutations in primary tumor tissue
by exome sequencing. We identiﬁed 25 common mutations in
both samples, and 83% of mutations identiﬁed in the primary
tumor could be detected in the cell-free DNA.CONCLUSIONS: The presence of ctDNA reﬂects tumor pro-
gression, and detection of ctDNA can predict VP and recurrence,
especially extrahepatic metastasis within 2 years. Our study
demonstrated the usefulness of ctDNA detection and
sequencing analysis of cell-free DNA for personalized treatment
of liver cancer. (Cell Mol Gastroenterol Hepatol 2015;1:516–534;
http://dx.doi.org/10.1016/j.jcmgh.2015.06.009)
Keywords: Circulating Tumor DNA; Exome Sequencing; Hepa-
tocellular Carcinoma; Whole-Genome Sequencing.
ancer genome sequencing has been performed andCapplied clinically in several cancers. A subgroup of
patients with non-small-cell lung cancer have speciﬁc mu-
tations in the epidermal growth factor receptor (EGFR) gene
that correlate with clinical responsiveness to the tyrosine
kinase inhibitor geﬁtinib.1,2 Patients with a colorectal tumor
bearing mutated K-ras did not beneﬁt from cetuximab,
whereas patients with a tumor bearing wild-type K-ras did
beneﬁt from cetuximab.3 Clinical responses to imatinib
depend on the exonic location of KIT mutations in gastro-
intestinal stromal tumors.4 Hence, recent advances in cancer
genome analysis and genome-based diagnosis are enabling
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treatment. Cancer genome sequencing is also used to
monitor the state of cancer progression.5,6
In hepatocellular carcinoma (HCC), unlike in many other
solid tumors, diagnosis is often based on contrast-enhanced
studies, such as computerized tomography or magnetic
resonance imaging, and treatment is often undertaken
without percutaneous tumor biopsy.7,8
Circulating tumor DNA (ctDNA) carrying tumor-speciﬁc
sequence alterations have been found in the cell-free frac-
tion of blood.9,10 Several studies have indicated that ctDNA
carrying speciﬁc KRAS mutations are useful for diagnosis
and prognostic prediction in some solid tumors.11,12
Therefore, ctDNA collected without percutaneous tumor
biopsy might be an innovative tool to analyze the cancer
genome of HCC as a so-called liquid biopsy.
Several studies have shown the utility of ctDNA in
monitoring tumor dynamics in patients with various solid
cancers5,6,13–15 and in identifying mutations associated
with acquired drug resistance in advanced cancers.6
Recent studies have shown that ctDNA contains the
comprehensive tumor genome, including variants origi-
nating from multiple independent tumors.16,17 Therefore,
ctDNA is expected to be an effective tool to overcome
tumor heterogeneity.
In HCC, Chan et al16 showed that shotgun sequencing of
plasma samples from HCC patients would allow cancer-
associated copy number aberrations and mutations to be
analyzed noninvasively and in a genomewide fashion. How-
ever, ctDNA of HCC has not been well characterized so far. In
this study, we detected cancer-speciﬁc genomic rearrange-
ments on 46 HCCs by whole-genome sequencing and vali-
dated some of them by polymerase chain reaction (PCR)
using ctDNA detection in patient sera. We investigated
whether ctDNA levels reﬂect HCC tumor dynamics and could
be used as a predictor of poor prognosis by quantifying each
of the cancer-speciﬁc genomic rearrangements. We have also
investigated whether exome sequencing of cell-free DNA
(which is deﬁned in this paper as whole extracellular DNA
circulating in blood containing ctDNA) in a patient with liver
cancer could identify somatic mutations in cancer tissue.Materials and Methods
Patients
Eligible patients included those who underwent hepa-
tectomy or liver transplantation for HCC and combined
hepatocellular and cholangiocarcinoma (cHCC/CC) at Hir-
oshima University during the period between October 2009
and January 2012. For 46 of these patients, sequential
serum samples were available; somatic rearrangements had
been identiﬁed by whole-genome sequencing of tumor tis-
sue, and control lymphocytes were recruited. We quantiﬁed
ctDNA in a total of 50 serial serum samples by means of
real-time PCR. We performed exome sequencing of primary
tumor tissue and cell-free DNA from plasma samples after
transcatheter arterial chemoembolization (TACE) of another
patient with cHCC/CC. The study protocol was approved
by the Human Ethics Review Committee of HiroshimaUniversity and RIKEN, and a signed consent form was ob-
tained from each patient.
Sample Collection and Storage
A tumor tissue samples were obtained immediately after
the liver resection and were frozen in liquid nitrogen and
stored at 80C. Serum samples obtained by venipuncture
using 5-mL serum-separating tubes (P1; SRL, Tokyo, Japan)
were centrifuged at 3500 rpm for 10 minutes, and the su-
pernatant was kept frozen at 80C for later use in DNA
preparation. Plasma samples obtained by venipuncture us-
ing 5-mL EDTA-2K blood collection tubes (VP-DK050K;
Terumo, Tokyo, Japan). The blood was centrifuged at 3500
rpm for 10 minutes, and the supernatant (plasma) was
collected and centrifuged at 12,000 rpm for 10 minutes.
Then the supernatant was collected and stored at 80C for
later use in DNA preparation.
Tumor Markers
We used a chemiluminescent immunoassay (Fujire Bio,
Tokyo, Japan) and chemiluminescent enzyme immunoassay
(Abbott Laboratories, Abbott Park, IL) to analyze a-feto-
protein (AFP) and des-g-carboxy prothrombin (DCP),
respectively. Thresholds for AFP and DCP abnormalities
were deﬁned as 10 ng/mL and 30 mAU/mL, respectively.
Whole-Genome Sequencing
DNA was extracted from frozen tumor tissues and lym-
phocytes, and 500-bp insert Illumina libraries were pre-
pared from 1 mg of DNA from each sample. The libraries
were analyzed using massively parallel sequencing on the
HiSeq2000 platform (Illumina, San Diego, CA) with 101-bp
paired reads according to the manufacturer’s instructions.
Average sequencing depths of the cancer and control
(lymphocyte) genomes were about 40x and 30x, respec-
tively, after the removal of PCR duplicates.
Somatic Genomic Rearrangement Calls
Read pairs were mapped to the human reference
genome GRCh37 using Burrows-Wheeler Aligner software
(bio-bwa.sourceforge.net/).18 Cancer-speciﬁc somatic rear-
rangements were identiﬁed as described previously else-
where.19 Brieﬂy, inconsistent read pairs that occurred
within 500 bp of each other were considered to support the
same rearrangement. We identiﬁed candidate rearrange-
ments in both tumor (support read pairs 4) and normal
tissue (support read pairs 1) samples, and we also iden-
tiﬁed tumor-speciﬁc rearrangement candidates. To exclude
mapping errors, we performed a Basic Local Alignment
Search Tool (BLAST) search of read pairs that supported
rearrangements against the reference genome. Read pairs
that mapped with the correct orientation and distance
(500 bp) with an E-value <107 were excluded. Reads
that mapped with more than two mismatches were also
discarded. After ﬁltering, candidates supported by 4 read
pairs and at least one perfect match pair were considered
somatic rearrangements.
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For each cancer genome, we selected three somatic
rearrangements in which calls were supported by the
largest number of read pairs in each sample, and we
designed primers spanning the breakpoints (see
Supplementary Table 1). PCR of the breakpoints using these
primers was performed using DNA from the cancer and
lymphocytes as positive and negative controls, respectively.
The PCR products were conﬁrmed by Sanger sequencing,
and conﬁrmed primers were used for serum DNA PCR.Detection of Circulating Tumor DNA
(ctDNA) by PCR
Cell-free DNA was extracted from 100 mL of preoperative
serum by the SMI-TEST (Genome Science Laboratories,
Tokyo, Japan) according to the manufacturer’s instructions
and dissolved in 20 mL of distilled water. The extracted
ctDNA from serum samples was ampliﬁed by PCR using the
primers described in Supplementary Table 2. The 2.5 ng of
DNA samples from cancer tissue and from blood cells was
used as the positive and negative controls, respectively. We
also used cell-free DNA extracted from the serum of chronic
hepatitis C (HCV) and hepatitis B (HBV) virus patients
without HCC as negative controls.
We loaded 1 mL samples of cell-free DNA dissolved in 20
mL of distilled water. We also performed nontemplate
ampliﬁcation scattered among samples, but no false positive
results were observed. PCR was performed in a total volume
of 50 mL, consisting of 5 mL of 10x PCR buffer for KOD-Plus-
Neo, 0.2 mM of dNTPs, 1.5 mM of MgSO4, 0.3 mM of each
primer, 1 mL of the DNA solution, and 1 U/50 mL of KOD-
Plus-Neo (Toyobo, Osaka, Japan).
We tried to detect ctDNA using one to three primer sets
among patients. We initially performed PCR in a two-step
cycle as recommended by the manufacturer’s instructions
(KOD-Plus-Neo): initial denaturation at 94C for 2 minutes,
followed by 40 cycles of denaturation at 98C for 10 sec-
onds, then extension at 68C for 30 seconds. In cases of
ampliﬁcation failure, we performed PCR in a three-step cy-
cle according to the manufacturer’s instructions, as follows:
initial denaturation at 94C for 2 minutes, followed by 40
cycles of denaturation at 98C for 10 seconds, annealing
at the primer-speciﬁc melting temperature (shown in
Supplementary Table 2) for 30 seconds, and extension at
68C for 30 seconds. If the band was not observed after
electrophoresis of the PCR product in positive controls, we
set the annealing temperature lower. If smeared bands
made judgment was difﬁcult, we set the annealing temper-
ature higher and/or set the extension time to 10 s/kb.
Then we evaluated whether the sample was positive or
negative under conditions in which ampliﬁcation was
observed clearly in positive controls and smeared bands were
not observed in negative controls or cell-free DNA after
electrophoresis of the PCR product. The conditions we used
for judgment are shown in Supplementary Table 2. We
deﬁned the result to be positive when ctDNA was ampliﬁed
by one or more of the primer sets. We synthesized DNA oligos
based on mutated cancer genomes (Integrated DNATechnologies, Coralville, IA) (Supplementary Table 3) and
made a serial dilution. To conﬁrm the robustness of the re-
sults, we performed PCR for each template using 13 primer
sets.
Quantiﬁcation of ctDNA in Sera
Real-time PCR analysis was performed on samples that
tested positive in the detection assay and for which serial
serum samples were available. PCR was performed using
the Mx300P System (Applied Biosystems, Foster City, CA)
according to the instructions provided by the manufacturer.
We prepared 10 mL of EXPRESS SYBR GreenER qPCR
SuperMix Universal (Applied Biosystems), 200 nM of for-
ward primer, 200 nM of reverse primer, 25 mM of ROX
Reference Dye, 1 mL of DNA, and 7.8 mL of distilled water.
The above custom-synthesized DNA oligos were diluted
from 105 with distilled water, as shown in Supplementary
Table 2, to produce a series of standard quantitative PCR
preparations used to generate the standard curve
(Figure 1). The optimal threshold in each assay was chosen
automatically in MxPro QPCR Software Version 4.10 (Agi-
lent Technologies, Santa Clara, CA). The lower threshold is
indicated using a dotted line in Figure 5. Each sample was
processed in a set of triplicate counterparts. The cycling
programs are shown in Supplementary Table 2. In cycling
program A, the sample was heated for 20 seconds at 95C
for denaturing, followed by a PCR cycling program con-
sisting of 40 three-step cycles of 5 seconds each at 5C, and
20 seconds at 60C. In cycling program B, the sample was
heated for 10 minutes at 95C for denaturing, followed by a
PCR cycling program consisting of 40 three-step cycles of 30
seconds each at 95C, 60 seconds at 55C, and 60 seconds at
72C.
Exome Sequencing of Plasma Cell-Free DNA
Plasma cell-free DNA was extracted from 1 mL of plasma
from one patient with metastasis (case C1) using the
QIAamp circulating nucleic acid kit (Qiagen, Valencia, CA)
according to the manufacturer’s instructions. The DNA was
eluted into 50 mL of buffer AVE (RNasa-free water con-
taining 0.04% sodium azide), eluted twice through each
column, and stored at 20 C. The quantity of the extracted
DNA was analyzed by the Qubit ﬂuorometer (Invitrogen/
Life Technologies, Carlsbad, CA). We subjected 50 ng of
plasma cell-free DNA, primary tumor DNA, and lymphocyte
DNA to Illumina Nextera library generation, and targeted
enrichment was performed using the Nextera Rapid Capture
Exome kit (Illumina) according to the manufacturer’s in-
structions. The enrichment system included 37 Mega-base
pairs of protein-coding exons from the human genome,
amounting to 214,405 exons. Sequencing was performed
with HiSeq2500 (Illumina) with paired-end 101-bp reads.
The coverage in targeted regions after the removal of PCR
duplicates is shown in Table 1.
Variant Detection
Sequencing reads were aligned to the U.S. National
Center for Biotechnology Information (NCBI) reference
Table 1.Coverage in Targeted Regions
Target Regions Lymphocyte Tissue cfDNA
Number 212,158 212,158 212,158
Total length 37,105,383 37,105,383 37,105,383
Average coverage 106.9 100.4 94.1
No. with
coverage <30
69,030 100,139 76,914
Total length with
coverage <30
20,405,685 25,663,716 22,051,522
Minimum
coverage (%)
1 x 99.71 98.38 99.50
5 x 98.74 96.01 98.26
10 x 97.03 93.23 96.40
20 x 92.60 87.79 92.07
40 x 81.16 76.12 80.82
80 x 53.46 51.91 50.80
100 x 41.27 41.13 37.51
Figure 1. Quantitative ranges. Quantitative ranges were from 105 copies to 5 copies in the most sensitive assay and 105
copies to 102 copies in the least sensitive assay, as shown in the upper and lower panels, respectively.
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Workbench 6.5.1 and 7.5 software (CLC Bio, Aarhus,
Denmark). We analyzed our sequencing data derived from
cell-free DNA, primary tumor, and control lymphocytes us-
ing the Probabilistic Variant Detection Tool and Low Fre-
quency Variant Detection Tool included in the Genomics
Workbench.
Probabilistic Variant Detection Tool. The algorithm of
Probabilistic Variant Detection combines a Bayesian model
with a maximum likelihood approach to calculate prior
and error probabilities for the Bayesian model. Para-
meters: Minimum coverage ¼ 40; Maximum expected
variant ¼ 3 in cancer, 2 in control; Ignore nonspeciﬁc
matches ¼ Yes; Require presence in both forward and
reverse reads ¼ Yes; Ignore variants in nonspeciﬁc match ¼
Yes; variant probability ¼ 90.0; Required variant count ¼ 15
in indels.
Low Frequency Variant Detection Tool. The Low Fre-
quency Variant Detection Tool performs a statistical test at
each site to determine whether the nucleotides observed in
the reads at that site could be due simply to sequencing
errors, or whether they would be signiﬁcantly better
explained by the presence of one or more different allelespresent in the sample at unknown frequency. In the latter
case, a variant corresponding to the signiﬁcant allele is
called and the frequency is estimated. Parameters: Required
520 Ono et al Cellular and Molecular Gastroenterology and Hepatology Vol. 1, No. 5signiﬁcance (%) ¼ 1.0; Ignore broken pairs ¼ Yes; Ignore
nonspeciﬁc matches ¼ Reads; Minimum coverage ¼ 20;
Minimum count ¼ 2; Minimum frequency (%) ¼ 1.0; Base
quality ﬁlter ¼ Yes; Neighborhood radius ¼ 5; Minimum
central quality ¼ 20; Minimum neighborhood quality ¼ 15;
Read direction ﬁlter ¼ Yes; Direction frequency (%) ¼ 5.0;
Read position ﬁlter ¼ No; Relative read direction ﬁlter ¼
Yes; Signiﬁcance (%).
Variants called in the lymphocytes or found in the
dbSNP 137 database, the HapMap database, or the 1000
Genomes Project were considered to be germline muta-
tions. The remaining mutations were considered somatic
mutations.Somatic Mutation Validation by
Sanger Sequencing
In cell-free DNA, primary tumor and matched lympho-
cytes, Sanger sequencing of nonsynonymous variantsFigure 2. Detection of circulating tumor DNA (ctDNA) by
rearrangements. Gel electrophoresis of PCR products. The
ampliﬁed by PCR with the use of primers designed to detect brea
Supplementary Table 1). DNA extracted from cancer tissue sam
from blood cells was used as a negative control (B). (A, B) Pa
hepatocellular carcinomas (HCCs) in cases H1–H4 (A) and H5–
Each circle plot represents validated somatic rearrangements in
(green), deletions (blue), inversions (red), and tandem duplication
(F, G) DNA extracted from serum of chronic hepatitis C (HCV)
conﬁrmed not to be ampliﬁed by PCR using these primer. Re
tissue. The red arrow shows the target product.identiﬁed in both ctDNA and primary tumor was performed
to conﬁrm the presence of the somatic mutations identiﬁed
by the variant detection analysis. Primers were designed
using CLC Genomics Workbench 6.5.1 (Supplementary
Table 4). PCR was performed in a total volume of 50 mL,
consisting of 5 mL of 10x PCR buffer for KOD-Plus-Neo, 0.2
mM of dNTPs, 1.5 mM of MgSO4, 0.3 mM of each primer, 1 mL
of the DNA solution, and 1 U/50 mL of KOD-Plus-Neo
(Toyobo). The ampliﬁcation conditions included initial
denaturation at 94C for 2 minutes, followed by 40 cycles of
denaturation at 98C for 10 seconds, annealing at 64C for
30 seconds, extension at 68 C for 10 seconds, followed by 5
minutes of ﬁnal extension at 68C. The ampliﬁed DNA
fragments were separated onto a 2% agarose gel and pu-
riﬁed using the FastGene Gel/PCR Extraction kit (Nippon
Genetics, Tokyo, Japan). Nucleotide sequences were deter-
mined using BigDye Terminator v3.1 cycle sequencing kit
(Applied Biosystems). Sanger chromatograms were
analyzed using CLC Genomics Workbench 6.5.1.polymerase chain reaction (PCR) targeting for somatic
ctDNA extracted from preoperative serum samples (S) was
kpoints of somatic rearrangements in each of the tumors (see
ples was used as a positive control (C), and DNA extracted
tients with positive ctDNA. Upper panel: Circos plots of the
H7 (B) who tested positive preoperatively for serum ctDNA.
each of the HCCs. Lines show chromosomal translocations
s/translocations (orange). (C–E) Patients with negative ctDNA.
(N1) and hepatitis B (HBV) (N2) patients without HCC were
d numbers show the amounts of DNA extracted from tumor
Figure 2. (continued).
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Figure 2. (continued).
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Figure 2. (continued).
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The cumulative incidence of recurrence and extrahe-
patic metastasis within 2 years and cumulative survival
rate after surgery were calculated using the Kaplan-Meier
technique, and differences in the curves were tested using
the log-rank test. Differences among groups were exam-
ined for statistical signiﬁcance using the Fisher exact test
or Pearson chi-square test, as appropriate. The Mann-
Whitney U test was used for comparison of AFP levels,
DCP levels, tumor size, and tumor numbers. Independent
risk factors predicting microscopic vascular invasion of
the portal vein (VP) were analyzed using stepwise Cox
regression analysis. These analyses were performed using
Statistical Package for Social Sciences version 11.0.1J
(SPSS/IBM, Chicago, IL). P < .05 was considered statisti-
cally signiﬁcant.
Results
Detection of ctDNA by Polymerase Chain
Reaction Immediately Before the Initial Surgery
For each of the liver cancer genomes, we selected three
somatic rearrangements and designed primers spanning
their breakpoints to detect cancer-speciﬁc sequences in
blood, based on their whole-genome sequencing data.
Figure 2 shows the PCR detection of ctDNA in serum cell-
free DNA, cancer tissue DNA, and blood-cell DNA as a
negative control. We also conﬁrmed that DNA extracted
from serum of chronic HCV and HBV patients without HCC
was not be ampliﬁed by PCR using these primers (see
Figure 2F and G). Among 46 patients with somaticTable 2.Summary of Clinical Characteristics of Patients
Characteristic Status of ctDNA Before Surg
No. of patients 46
Age at diagnosis (y) 67 (32–89)
Gender (M/F) 35/11
Etiology (HBV/HCV(SVR)/NBNC) 11/25 (6)/10
AFP (ng/mL) before surgery 60.5 (<0.5–57,410)
DCP (mAU/mL) before surgery 57.5 (2.6–135,640)
Tumor size (mm) 25.5 (10–140)
T (1/2/3/4) 11/18/15/2
T1 T2/T3 T4
M (0/1/2) 46/0/0
N (0/1/2) 46/0/0
Edmondson grading (I/II/III) 5/36/5
I, II/III
VP (0/1/2/3); VP (0/1/2/3) 35/9/1/1
VP 0/1,2,3
VV (0/1) 38/8
VA (0/1) 45/1
Note: AFP, a-fetoprotein; DCP, des-g-carboxy prothrombin; H
virologic response; NBNC, neither HBsAg (þ) nor anti-HCV (þ);
vein; VV, hepatic vein.
aFisher exact test.
bPearson chi-square test.
cMann-Whitney U test.rearrangements, ctDNA was detected in seven patients
(cases H1, H2, H3, H4, H5, H6, and H7) before the surgery
(see Figure 2A and B). The patient baseline characteristics
and detection of preoperative ctDNA by PCR are shown in
Table 2.
Circos plots20 in Figure 2A and B demonstrate genome-
wide views of somatic rearrangements in the seven HCC
patients who were positive for serum ctDNA. Somatic rear-
rangements targeted in ctDNA PCR are indicated by arrows.
In seven ctDNA-positive patients, the main tumor sizes were
statistically signiﬁcantly larger and the AFP and DCP levels
and the rate of VP were statistically signiﬁcantly higher than
in the remaining 39 patients (P ¼ <.001, .004, <.001, and
.046, respectively) (see Table 2). The result of the lowest limit
of detection assay (Figure 3) suggests that detection is
possible if there are at least 10–100 copies of DNA.Cumulative Incidence of Recurrence,
Extrahepatic Metastasis, and Survival Rate
The cumulative incidence of recurrence and extrahepatic
metastasis within 2 years after hepatic resection in the
ctDNA-positive group and the ctDNA-negative group are
illustrated in Figure 4. The cumulative incidence of recur-
rence and extrahepatic metastasis in the ctDNA-positive
group was statistically signiﬁcantly worse than in the
ctDNA-negative group (P ¼ .0102 and .0386, respectively).
Although the ctDNA-positive group was expected to have
poorer survival than the ctDNA-negative group, there was
no statistically signiﬁcant difference in the cumulative sur-
vival rate between the two groups (P ¼ .0730).ery ctDNA Positive ctDNA Negative P Value
7 39
68 (51–86) 67 (32–89) .426
5/2 30/9 .541a
1/4(2)/2 10/21 (4)/8 .775b
10,100 (12.7–57,410) 15.8 (<5–35330) .004c
23,156 (866–135,640) 37 (2.6–16123) <.001c
73 (35–140) 23 (10–125) <.001c
0/3/3/1 11/15/12/1
3/4 26/13 .216
a
7/0/0 39/0/0
7/0/0 39/0/0
0/6/1 5/30/4
6/1 35/4 .580a
3/4/0/0 32/5/1/1
3/4 32/7 .046a
4/3 34/5 .089a
6/1 39/0 .152a
BV, hepatitis B virus; HCV (SVR), hepatitis C virus sustained
VA, hepatic artery; VP, microscopic vascular invasion to portal
Figure 3. Lowest limit of detection. To conﬁrm the lowest limit of detection, custom synthesized DNA oligos that were diluted
from 105 copies to 10 copies with distilled water were ampliﬁed by polymerase chain reaction. They remained detectable in
any condition when at least 10–100 copies of DNA were present.
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Vascular Invasion to Portal Vein
Of 46 patients, 11 patients had HCC with VP. Univariate
analysis identiﬁed the following factors associated with VP
before surgery: ctDNA (positive, P ¼ .046), AFP (>100 ng/
mL; P ¼ .042), and DCP (>100 IU/mL; P ¼ .042) (Table 3).
Of these, multivariate analysis identiﬁed the presence of
ctDNA (positive: OR 6.10; 95% CI, 1.11–33.33; P ¼ .038) as
an independent factor (see Table 3).Quantiﬁcation of Circulating Tumor
DNA in Serum
The ctDNA was quantiﬁed by real-time quantitative PCR
in serial serum samples before and after the surgery from
the ﬁve ctDNA-positive patients. The time courses of ctDNA
levels and serum levels of AFP and DCP for these patients
are shown in Figure 5 along with treatment information.
Overall, the levels of serum ctDNA increased with disease
progression and responded to the treatments.
Case H1 (see Figure 5A) had multiple tumor lesions
that were resected for down-staging. The patientunderwent HAIC (hepatic arterial infusion chemotherapy)
with low-dose FP (5-ﬂuorouracil þ platinum) therapy,
TACE (transcatheter arterial chemoembolization), and
5FU-IFN (5-ﬂuorouracil þ interferon) treatment. The pa-
tient showed stable disease for 1 year after surgery but
developed bone metastasis 13 months after surgery. It is
notable that ctDNA quantiﬁed using primer 2 in sera were
still positive at this time point even though both serum
AFP and DCP were negative after the tumor resection. The
patient then underwent a combination of systemic
chemotherapy and TACE, which suppressed tumor pro-
gression until 25 months after the surgery. The patient had
progressive disease thereafter and died 40 months after
surgery. The ctDNA levels decreased during the period of
stable disease but were detectable throughout the obser-
vation period and increased during the period of pro-
gressive disease.
Case H2 (see Figure 5B) had multiple tumor lesions in
the right lobe that were removed by curative resection. The
patient underwent TACE 1 month before surgery, and un-
derwent HAIC with low-dose FP (5-ﬂuorouracil þ platinum)
as adjuvant therapy, showing no recurrence until imaging
Figure 4. The cumulative incidence of recurrence and extrahepatic metastasis within 2 years after hepatic resection.
The cumulative incidence of recurrence (left) and extrahepatic metastasis (right) of the circulating tumor DNA (ctDNA)-positive
group (green line) were statistically signiﬁcantly worse than that of the ctDNA-negative group (red line) (P ¼ .0102 and .0386,
respectively).
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surgery. Even though serum AFP and DCP levels had
became negative 3 and 5 months after the curative resec-
tion, ctDNA was detected throughout the observation.
Although the patient underwent TACE, intrahepatic, lung,
and peritoneal metastases appeared. The serum ctDNA
increased with the AFP and DCP, along with the disease
progression.
Case H3 (see Figure 5C) had multiple tumor lesions in
the right lobe that were curatively resected. The patient
underwent TACE 1 week before surgery. Serum ctDNA
levels decreased along with AFP and DCP after surgery.
Although the DCP level became negative, AFP and ctDNA
were detected throughout the observation period. After
the appearance of multiple intrahepatic recurrences, TACE
failed to suppress the progression. Interestingly, DCP
decreased after subsequent 5FU-IFN (5-ﬂuorouracil þ
interferon) treatment and TACE along with ctDNA, but
AFP did not. All three markers increased at ﬁnal
worsening.
Case H4 (see Figure 5D) had one HCC lesion that was
treated with TACE 1 month before surgery. The patient
underwent HAIC as adjuvant therapy. Metastasis to the lungwas detected by imaging 4 months after surgery. Accord-
ingly, HAIC was switched to systemic chemotherapy and
bronchial arterial embolization. Although the ctDNA quan-
tiﬁed using primer 1 decreased after surgery but never
became negative and rebounded with disease progression,
the ctDNA quantiﬁed using primer 3 decreased after surgery
and maintained a negative result even during the period of
progressive disease.
Case H5 (see Figure 5E) had a 10-cm HCC in the right
lobe that was removed by partial hepatectomy. The patient
underwent TACE 2 weeks before surgery. The HCC was the
poorly > moderately differentiated type with microscopic
vascular invasion. This patient had not developed a recur-
rence more than 3 years after surgery.Serum ctDNA Dynamics After TACE
Of the seven patients who tested positive for ctDNA, six
received TACE before surgery. Serial serum samples at 1, 4,
and 6 days after TACE were available in cases H2 and H3.
Figure 6A shows the ctDNA dynamics of ctDNA quantitation
after TACE in these two patients. The ctDNA levels of cases
H2 and H3 increased 5- and 10-fold compared with pre-
Table 3.Univariate and Multivariate Analyses of Factors Associated With Microscopic Vascular Invasion to Portal Vein
Status of ctDNA Before Surgery
Univariate analysis Multivariate analysis
OR (95% CI) P Value OR (95% CI) P Value
ctDNA before surgery: positive 6.10 (1.11–33.33) .046a 6.10 (1.11–33.33) .038b
AFP (ng/mL) before surgery: >100 4.51 (1.01–20.1) .042c
DCP (mAU/mL) before surgery: >100 4.51 (1.01–20.1) .042c
Tumor size: >50 mm 2.76 (0.61–12.51) .175a
Note: AFP, a-fetoprotein; CI, conﬁdence interval; ctDNA, circulating tumor DNA; DCP, des-g-carboxy prothrombin; OR, odds
ratio.
aPearson chi-square test.
bStepwise Cox regression analysis.
cFisher exact test.
September 2015 ctDNA Analysis for Liver Cancer 527TACE levels and peaked 4 days after TACE. We investigated
whether ctDNA after TACE could be detected in three pa-
tients (cases H8, H9, and H15) 4 days after TACE, and we
were able to detect it in two patients, cases H8 and H9 (see
Figure 6B).Figure 5. Monitoring of serial circulating tumor DNA (ctDNA
polymerase chain reaction in sera serially sampled before and a
H1–H5). The ﬁgure shows the time course of serum levels of
(DCP) with their clinical events and treatments. Levels of ctDNA
using DNA extracted from tumor tissue.Exome Sequencing of Cell-Free DNA as a
Liquid Biopsy
To explore the potential of cell-free DNA sequencing as
a diagnostic tool, we performed exome sequencing of pri-
mary tumor tissue DNA, leukocyte DNA, and cell-free DNA) levels. The ctDNA was quantiﬁed by real-time quantitative
fter surgery from the four patients with positive ctDNA (cases
ctDNA, a-fetoprotein (AFP), and des-g-carboxy prothrombin
are expressed as a ratio relative to levels of those obtained
Figure 5. (continued).
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Figure 5. (continued).
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Figure 6. Circulating tumor DNA (ctDNA) dynamics after undergoing transcatheter arterial chemoembolization (TACE).
(A) Serum ctDNA levels at 1, 4, and 6 days after TACE are shown as a solid line, and serum aminotransferase (AST) and alanine
aminotransferase (ALT) levels are shown as dotted lines. The x-axis shows the number of days after TACE. The y-axis on the
left indicates the fold change of serum ctDNA levels compared with that before TACE, and the y-axis on the right indicates
serum AST, ALT, AFP (a-fetoprotein), and des-g-carboxy prothrombin (DCP) levels. The ctDNA levels of cases 2 and 3
increased 5- and 10-fold compared with before TACE, respectively. The ctDNA levels peaked 4 days after TACE was per-
formed. (B) The ctDNA became detectable 4 days after TACE (S2) in two of three patients (cases H8 and H9) who were
negative for ctDNA before TACE (S1). DNA extracted from cancer tissue samples was used as a positive control (C), and DNA
extracted from blood cells were used as a negative control (B).
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intrahepatic metastasis of cHCC/CC. The clinical course of
case C1 is shown in Figure 7A. One cHCC/CC lesion was
resected in the right lobe, and the patient underwent HAIC
as adjuvant therapy, but peritoneal metastasis and intra-
hepatic recurrence appeared 13 months after the surgery.
Although the patient underwent TACE, partial hepatectomy
with diaphragm resection, and systemic GEM-IFN
(gemcitabine þ interferon) treatment, multiple intra-
hepatic recurrences appeared 2 years after the ﬁrst sur-
gery. Pathologic review indicated that the resected tumors
were a recurrence of the previously resected cHCC/CC.
TACE was performed for those intrahepatic recurrent le-
sions, and we obtained blood serially on the time course
after TACE and extracted cell-free DNA from these plasma
samples.
The amount of the total cell-free DNA obtained at each
time point for case C1 is shown in Figure 7B. The cell-free
DNA was most abundant in plasma on day 2 after TACE,
and this sample was analyzed by exome sequencing to
identify somatic mutation candidates in the tumor. We also
performed exome sequencing of the primary resected tissue
sample of this patient and compared the somatic mutational
proﬁles. Comparing with exome sequencing data of theleukocyte DNA, we identiﬁed 45 nonsynonymous somatic
mutations in the cell-free DNA and 71 nonsynonymous so-
matic mutations in the primary tumor tissue using the
Probabilistic Variant Detection Tool. Among them, 25 mu-
tations were detected in both the cell-free DNA and the
primary resected sample (Supplementary Table 5).
Subsequently we reanalyzed the mutations that were
detected either in primary tumor tissue or cell-free DNA
using the Low Frequency Variant Detection Tool. We found
that 22 of 46 variants that had not been detected in cell-free
DNA but had been detected in primary tumor tissue using
the Probabilistic Variant Detection Tool were detected by
the Low Frequency Variant Detection Tool (see Figure 5C).
Combining these results, 58 of 91 somatic mutations (64%)
were commonly detected in both cell-free DNA and primary
tumor tissue.Discussion
In this study we successfully quantiﬁed ctDNA using
100-mL serum samples. The levels of ctDNA reﬂected the
effect of therapy and the progression of the cancer, as
previously reported elsewhere.5,6,13–15 Measurement of
ctDNA provided important clinical information. Of the
Figure 7. Exome sequencing of primary tumor and cell-free DNA. (A) The clinical course of case C1. Case C1 had one
combined hepatocellular and cholangiocarcinoma (cHCC/CC) lesion in the right lobe that was removed by curative resection.
Transcatheter arterial chemoembolization (TACE) was performed for intrahepatic recurrent lesions 2 years after the ﬁrst sur-
gery. We performed exome sequencing of cell-free DNA after the TACE and the primary tumor (red star). (B) The amount of
total cell-free DNA extracted from the plasma samples serially obtained after TACE. Cell-free DNA was most abundant in
plasma 2 days after TACE, and was therefore used for exome sequencing analysis. (C) Common mutations in cell-free DNA
and primary tumor. Somatic mutations detected by probabilistic variant detection and low frequency variant detection are
indicated by the red and pink boxes, respectively.
September 2015 ctDNA Analysis for Liver Cancer 531seven patients who tested positive for ctDNA before sur-
gical resection, six patients developed recurrence, and four
developed extrahepatic metastases (see Figure 4).
Furthermore, in one patient (case H1) ctDNA was still
positive even when both AFP and DCP became negative or
fell below the threshold after curative resection (see
Figure 5A). This suggests that, in some patients, ctDNA
might be a better and more sensitive biomarker for HCC
than the conventional tumor markers AFP and DCP in
predicting recurrence and determining the necessity of
further chemotherapy.
We also showed that the TACE procedure actually
increased or enriched ctDNA levels in cell-free DNA in blood.
This increase might result from a large release of tumor
DNA from cancer tissue damaged by TACE. Thus, when we
routinely perform TAE or TACE during diagnostic angiog-
raphy for HCC, we can obtain a larger amount of tumor-
derived DNA from blood and analyze mutational proﬁles
of liver cancers as a liquid biopsy.In this study we also demonstrated the potential use-
fulness of exome sequencing of cell-free DNA. We used
plasma samples for exome sequencing instead of serum
samples because serum is likely to contain a higher con-
centration of normal cell-free nucleic acids, produced from
normal nucleated cells during clotting,21 which would
reduce the relative frequency of tumor-derived mutant al-
leles and make them more difﬁcult to detect. We detected
25 common somatic mutations identiﬁed in cell-free DNA
and primary tissue that had been resected 2 years previ-
ously (see Figure 7C). Fujimoto et al19 indicated that no
common somatic mutations were identiﬁed in whole
genomic regions of the two pairs of multicentric tumors. Our
results suggest that the patients had recurrence but not
multicentric tumors.
The Low Frequency Variant Detection Tool detected 22
of 46 variants in primary tumor tissue that had not been
detected in cell-free DNA. This ﬁnding suggests that it might
be better to perform deeper sequencing and to detect low
Figure 7. (continued).
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September 2015 ctDNA Analysis for Liver Cancer 533frequency variants when analyzing cell-free DNA. The allele
frequency ratio (cell-free DNA/primary tumor tissue) was
calculated to estimate the proportion of ctDNA to total cell-
free DNA. The median allele frequency ratio was 0.79, and
the average mutant allele frequency in cell-free DNA was
22% in this study.
Recent studies of cell-free DNA using ultra-deep
sequencing have found that mutant reads of cell-free DNA
varied between <0.1% to 38.4% but were mostly less than
5%.22,23 These results support the hypothesis that the
proportion of ctDNA to the total cell-free DNA can be
enriched by the TACE procedure.
A potential reason for the remaining discrepancy is tu-
mor heterogeneity. When tumor tissue sampling was per-
formed, it is unlikely that the majority of dominant clones
were captured. Another explanation might be molecular
evolution from the primary tumor to recurrent tumors due
to selection pressure over the course of several therapies.
Although further work is required to improve the anal-
ysis pipeline, we conclude that genome sequencing analysis
of cell-free DNA in plasma after TACE and other embolic
procedures are performed is a promising method of genome
scanning. In particular, analyzing cell-free DNA after TACE
in unresectable and recurrent cases as a liquid biopsy to
establish cancer genome proﬁles might be useful in the
future to guide selection of an individualized therapeutic
regimen without requiring percutaneous biopsy. For
example, in case C1 we detected a GNAS E130G mutation by
cell-free sequence analysis, suggesting that the recurrent
tumors might respond to a mitogen-activated protein kinase
kinase inhibitor.24
Two phase III randomized clinical trials have shown that
sorafenib, a multitargeted tyrosine kinase inhibitor, im-
proves the overall survival of patients with advanced
HCC.25,26 Many other targeted agents that speciﬁcally block
tumor-associated signaling pathways using either small
molecular compounds or humanized monoclonal antibodies
to inhibit angiogenesis and tumor growth are being devel-
oped and tested in HCC.27–37 However, resistance is also
likely to become a problem with these drugs. Analysis of
ctDNA/cell-free DNA could be a useful tool in selecting the
best targeted agents in individual cases and as a guide to
switching targeted agents when resistance develops.
Interestingly, in case H4 the ctDNA dynamics varied
greatly depending on the primer set, each of which targeted
a different somatic rearrangement. This result suggests that
monitoring mutation proﬁles may be a useful method to
reveal the mechanism of the resistance.
In summary, we detected ctDNA in serum samples of
patients with advanced HCC and showed the usefulness of
ctDNA as a biomarker. We also demonstrated the potential
usefulness of exome sequencing of the cell-free DNA from
plasma after TACE. As we were only able to analyze a
relatively small number of cases due to the difﬁculty of
obtaining samples, additional validation should be per-
formed. We also concede that some cases remain unde-
tected due to low sensitivity because the lower limit of
detection assays were not identical among all primer sets.
Further study is necessary to develop more sensitive,simple, and cost effective measures and more robust anal-
ysis pipelines to improve the efﬁcacy of therapy against
advanced HCC.References
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